Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Kesios Therapeutics

Request full access

Novel therapeutics for multiple myeloma and other cancers

Cambourne, United KingdomFounded 2012Biotech & Life Sciences

About Kesios Therapeutics

Kesios Therapeutics Limited was a UK-based biotechnology company focused on developing treatments for multiple myeloma and other cancers with significant unmet medical needs. The company was founded in 2012 as a spin-out from Imperial College London, based on the research of Professor Guido Franzoso from the Department of Medicine. Kesios operated from laboratories at the Imperial College Incubator in London.

The company's core strategy was to target the NF-κB signaling pathway, which, when abnormally activated, allows cancer cells to survive. Kesios developed drug candidates to disrupt a novel target within this pathway, the GADD45β/MKK7 complex, aiming to selectively kill cancer cells without harming normal cells. The lead drug candidate, KES-0001, was a tripeptide designed to restore apoptosis (programmed cell death) in myeloma cells and was advancing towards clinical studies for multiple myeloma.

The company assembled an experienced management team, notably appointing Dr. Paolo Paoletti, the former president of GSK Oncology, as Executive Chairman and later CEO in 2015. This leadership also included Jane Robertson as Chief Medical Officer and Peter Charlton as Chief Scientific Officer. The business model was centered on advancing its pipeline through clinical trials to validate its therapeutic approach. Kesios secured funding from a syndicate of major international investors. In October 2014, it received £1.9 million in a seed round from Imperial Innovations. This was followed by a significant Series A financing round in December 2015, raising £19 million (approximately $28.6 million) from investors including Imperial Innovations, SV Life Sciences, and Abingworth. This funding was intended to advance KES-0001 through Phase I/II clinical trials.

However, the company faced challenges in replicating the foundational pre-clinical results. An investor, Abingworth, later reported that Kesios could not replicate the pre-clinical assays of the inventor, leading to the suspension of further development work. According to PitchBook, the company is now out of business as of November 2016.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
59.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Spinout, Biotech and Pharma, uk is8 life sciences, UKSU, UKSU2010, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Aug 2021 $30M $119M Imperial Innovations · SV Life Sciences · Abingworth —
DEBTDebt Aug 2016 $0 — SV Health Investors —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearEBITDAMargin
2026 —
2025 —
2024 —
2023 —
2022 —
2021 —
2020 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Kesios Therapeutics website traffic

Latest recorded traffic for Kesios Therapeutics is 20 monthly website visits, down 86.7% over the last three months.

Latest monthly visits20 3-month web change-86.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Kesios Therapeutics in the Cambourne ecosystem

Live from Dealroom

The Kesios Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Imperial Innovations

Series A2 investors entered at this stage

  • Abingworth
  • SV Life Sciences

Series B and later1 investor entered at this stage

  • SV Health Investors

Other known investors2 additional known investors

  • College of Medicine and Integrated Health
  • Imperial College London
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇬🇧 United Kingdom · Cambourne HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Kesios Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kesios Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.